The short version: what the trials actually show
Most GLP-1 myths start from a real observation and stretch it too far. The pivotal weight-loss trials of semaglutide (Wegovy) and tirzepatide (Zepbound) answer the four claims men ask about most often, and the answers are more useful than either the hype or the backlash.
| Claim | What the trial data say |
|---|---|
| Only for people with diabetes | STEP 1 and SURMOUNT-1 enrolled adults without diabetes |
| No lifestyle change needed | Every participant, including placebo, got diet and activity counseling |
| Always wastes muscle | Some lean mass is lost, and the share varies widely between studies |
| Must be taken forever | Stopping usually brings regain, so long-term plans matter |
Myth 1: GLP-1 medicines are only for diabetics
They started as diabetes drugs, but the weight-loss versions were tested in people without diabetes. In the STEP 1 trial, 1,961 adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and no diabetes took weekly semaglutide 2.4 mg or placebo. After 68 weeks, average weight change was minus 14.9% with semaglutide against minus 2.4% with placebo.
Tirzepatide followed the same pattern. In SURMOUNT-1, 2,539 adults without diabetes lost an average of 15.0%, 19.5% and 20.9% of body weight on the 5, 10 and 15 mg doses over 72 weeks, compared with 3.1% on placebo.
The brand names cause much of the confusion. Ozempic and Mounjaro are the diabetes products; Wegovy and Zepbound carry the weight-management approvals. Our page on semaglutide without diabetes covers who typically qualifies.
Myth 2: The injection does the work, so habits do not matter
Every number above came from people who were also being coached. In STEP 1, both groups received counseling every four weeks aimed at a 500-calorie daily deficit and 150 minutes of activity a week, as the STEP 1 extension paper describes. The placebo group shows what that counseling alone achieved: a modest loss of a few percent.
So the medicine was never tested as a replacement for diet and activity. It was tested as an addition to them, and that is how the labels describe its use. What the drug changes is how hard the deficit feels, because appetite drops and fullness comes sooner.
That shift has a practical catch. When you eat less, each meal carries more weight, so protein, fiber and fluids need deliberate attention. Our comparison of medical weight loss and dieting alone walks through where each approach fits.
Myth 3: GLP-1s always waste your muscle
Some of the weight lost on any calorie deficit is lean mass, and these medicines are no exception. The honest answer is that the share varies a lot. A 2024 review in Diabetes, Obesity and Metabolism found lean mass accounted for 40% to 60% of weight lost in some studies and about 15% or less in others.
Two details in that review matter for men. First, “lean mass” on a scan includes organs, water and bone, not only muscle. Second, the authors note imaging data suggesting part of the muscle change may be an adaptation to carrying a smaller body. Neither point makes muscle loss harmless, especially for men over 50, who start with less to spare.
What changes the outcome is what you do during the loss. Resistance training and enough protein protect muscle, and a body composition scan at the start shows whether it is working. Our sibling article on keeping muscle during a New Year weight-loss plan lays out a 12-week version, and our page on muscle loss on semaglutide goes deeper on the numbers.
Myth 4: Once you start, you can never stop
You can stop, but the trials show what usually follows. In the STEP 4 trial, people who had lost 10.6% over 20 weeks were split into two groups. Those who continued semaglutide lost a further 7.9% by week 68, while those switched to placebo regained 6.9%.
The STEP 1 extension followed people for a year after treatment ended. They had lost 17.3% on average and regained about two-thirds of it, finishing 5.6% below where they started. Most heart and blood sugar improvements drifted back toward baseline as well.
Tirzepatide looks similar. In SURMOUNT-4, people who lost 20.9% during a 36-week lead-in either continued or switched to placebo. The continuing group lost another 5.5%, while the placebo group regained 14.0%.
None of this makes the medicine a life sentence. It shows that obesity behaves like a chronic condition, and that coming off works better with a plan: habits built while on treatment, a slower step-down if your clinician recommends one, and follow-up weigh-ins. Our GLP-1 maintenance guide covers what that plan can include.
What these myths have in common
Each myth treats the medicine as either magic or a trap. The data describe something more ordinary: a tool that makes a calorie deficit easier to sustain, that works alongside training and nutrition, and whose effect fades when it stops unless something else takes its place.
The same balanced view applies to safety. These medicines carry real warnings, and some men should not take them at all, including anyone with a personal or family history of medullary thyroid carcinoma. Our explainer on the GLP-1 thyroid cancer warning covers where that warning comes from and what human studies have found since.
That framing also helps with newer claims. Products sold online as “research grade” semaglutide promise the same results without supervision, and the FDA has warned against them, as our article on research-use semaglutide explains.
How Ultimate Male puts the evidence to work
At our San Gabriel and Downey clinics, a medical weight loss plan starts with a medical evaluation, lab work and a body composition analysis, so we know your starting muscle and fat rather than just your weight. If semaglutide or tirzepatide fits your history and results, the provider sets and adjusts the dose, and regular check-ins track whether the loss is coming from fat.
We also talk about the end game at the first visit, not the last. If you want to know whether you are a candidate and what a realistic first year looks like, start with the free 10-minute phone call. A consultation is an evaluation, not a promise of medication.
